- CytomX Therapeutics Inc CTMX will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc ABBV decided not to advance the drug into additional studies.
- CytomX and AbbVie have also concluded their research activities under a 2016 Discovery License and Collaboration Agreement.
- AbbVie paid $30 million upfront in 2016 to ink the deal and another $15 million in milestones in 2017 for the start of toxicology studies.
- Related: CytomX Shares Move Higher On Collaborating Pact With This Famed COVID-19 Vaccine Maker.
- Updated Phase 2 data for CX-2029, released in January, suggested CX-2029 spurred a 21% objective response rate (ORR) among a group of heavily pre-treated patients with squamous esophageal cancer. The ORR was 10% in squamous non-small cell lung cancer.
- The adverse event profile was consistent with what was seen in Phase 1, with anemia being the most common side effect — experienced by 82.6% of patients in the trial.
- CytomX restructured its business in July to prioritize internal investments in its emerging pre-clinical and early clinical pipeline and laid off 40% of its workforce.
- In 2022, the company generated revenue of $53.2 million compared to $37.3 million a year ago, driven by higher estimated percentages of completion for R&D programs in the company's collaborations with AbbVie, Astellas Pharma Inc ALPMF and Bristol Myers Squibb & Co BMY.
- Cash, cash equivalents, and investments of $194 million exclude the $35 million cash payment received under the Moderna agreement in Q1 2023.
- Price Action: CTMX shares are down 15.10% at $1.52 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
